BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15758505)

  • 1. Raloxifene: results from the MORE study.
    Agnusdei D; Iori N
    J Musculoskelet Neuronal Interact; 2000 Dec; 1(2):127-32. PubMed ID: 15758505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
    Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
    J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
    Barrett-Connor E; Cauley JA; Kulkarni PM; Sashegyi A; Cox DA; Geiger MJ
    J Bone Miner Res; 2004 Aug; 19(8):1270-5. PubMed ID: 15231013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
    Qu Y; Wong M; Thiebaud D; Stock JL
    Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
    J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
    Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
    J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
    Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
    Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
    J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
    Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
    Inaba M
    Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.
    Lufkin EG; Whitaker MD; Nickelsen T; Argueta R; Caplan RH; Knickerbocker RK; Riggs BL
    J Bone Miner Res; 1998 Nov; 13(11):1747-54. PubMed ID: 9797484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.